.jpg)
What the Largest Clinical Trial of Its Kind Tells Us
In my years of integrative practice, few areas concern me more than the steady rise of autoimmune disease. Conditions like rheumatoid arthritis, thyroid disorders, inflammatory bowel disease, and psoriasis are no longer rare — they are increasingly common, often strike during a patient’s most productive years, and can be genuinely life-altering. And yet, conventional medicine has very little to offer in terms of prevention. Most of the conversation happens after a diagnosis has already been made.
That is why a landmark clinical trial published in The BMJ in 2022 caught my attention — and should catch yours. The VITAL study asked a straightforward question: Can two of the most widely used and well-tolerated supplements in integrative medicine — vitamin D and fish oil — actually prevent autoimmune diseases from developing in the first place? The findings are compelling, and I want to walk you through what they mean for you.
The VITAL trial (Vitamin D and Omega-3 Trial) enrolled 25,871 adults across the United States. Men were at least 50 years old; women were at least 55. The average participant age was 67, and the study population was racially diverse, reflecting a broad cross-section of older Americans. This was not a cherry-picked group of high-risk individuals — these were ordinary adults living in their communities.
Participants were randomly assigned to one of four groups for approximately 5.3 years: vitamin D3 at 2,000 IU per day, marine omega-3 fatty acids (fish oil) at 1,000 mg per day containing about 460 mg of EPA and 380 mg of DHA, both supplements together, or two placebos. Each year, participants reported any new doctor-diagnosed autoimmune conditions, and those reports were then reviewed and confirmed by two physicians who were blinded to which supplement each participant had received. The diagnoses tracked included rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, psoriasis, and inflammatory bowel disease, among others.
This kind of rigor matters. We are not talking about a small observational study or a short-term experiment. This was a large, long-term, randomized, placebo-controlled trial — the gold standard of clinical evidence — with physician-confirmed outcomes.
The results for vitamin D were striking. Among participants taking 2,000 IU of vitamin D3 daily, 123 people developed a confirmed autoimmune disease during the study period. Among those taking a placebo, 155 did. That translates to approximately a 22% reduction in risk. But here is what I find even more compelling: when researchers excluded the first two years of the study — accounting for the time it takes for the immune-modulating effects of vitamin D to build up — the risk reduction grew to approximately 39%. The longer people consistently took vitamin D, the stronger the protective effect became.
Fish oil showed a favorable trend as well, though its results were somewhat less definitive on their own. When only confirmed autoimmune disease cases were analyzed, the reduction did not quite reach statistical significance. However, when both confirmed and probable cases were combined, fish oil supplementation was associated with an 18% reduction in autoimmune events. Importantly, when both vitamin D and fish oil were taken together, the combination produced a 31% reduction in autoimmune disease risk compared to taking neither supplement — a meaningful finding for those of us who already recommend both as part of a foundational wellness protocol.
The study also offered some useful clues about which individuals seem to respond most to these supplements. The protective effect of vitamin D appeared strongest in people with a lower body mass index. Among leaner participants, the risk was nearly 40% lower than those on placebo. In individuals with higher BMIs, the effect was attenuated, which is consistent with what we know about vitamin D: excess body fat sequesters this fat-soluble vitamin, meaning higher doses may be needed in heavier individuals to achieve the same tissue concentrations.
For fish oil, the data showed a particularly meaningful benefit for those with a family history of autoimmune disease. Participants who had relatives with autoimmune conditions saw a hazard ratio of 0.66 on omega-3 supplementation — a 34% reduction in risk. This is a group I would pay particular attention to in practice, as a positive family history is often the most accessible indicator of elevated immune risk.
As an integrative clinician, I have long counseled patients on the immune-regulating properties of vitamin D and omega-3 fatty acids. This trial gives us powerful confirmation that those mechanisms are clinically meaningful over time.
Vitamin D, in its active hormonal form (1,25-dihydroxyvitamin D), binds to receptors found on virtually every cell of the immune system — including dendritic cells, T lymphocytes, B lymphocytes, and macrophages. It helps shift the immune system away from the inflammatory, self-attacking patterns associated with autoimmunity (driven by Th1 and Th17 immune cells, and cytokines like IL-2, IL-12, interferon-gamma, TNF-alpha, and IL-6) and toward a more regulated, tolerant state. It also reduces autoantibody production from B cells and promotes the development of regulatory T cells, which are essentially the immune system’s peacekeepers. When vitamin D is chronically deficient, these brakes on immune overactivation are weakened, and the risk of the immune system turning on the body’s own tissues increases.
Marine omega-3 fatty acids — specifically EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — modulate inflammation through several pathways. They influence cytokine activity, including TNF-alpha, IL-1 beta, IL-6, and CRP. They alter T cell activation and proliferation. And perhaps most importantly, they serve as the direct precursors to a class of molecules called specialized pro-resolving mediators — resolvins, protectins, and maresins — that do not merely suppress inflammation but actively help resolve it. This distinction matters enormously in autoimmune disease, where the failure to resolve inflammation is a central part of the pathology.
It is worth noting that a substudy of VITAL did not detect large changes in standard inflammatory blood markers like CRP after just one year of supplementation. This tells us that the autoimmune prevention effect likely operates through longer-term, more subtle shifts in immune regulation — not dramatic short-term changes in lab values. This is consistent with how I explain it to patients: these supplements are not anti-inflammatory drugs producing rapid effects; they are nutrients that, over time, help the immune system operate with greater intelligence and restraint.
I want to be straightforward about what this study does and does not tell us. The VITAL trial was a prevention study — it was designed to see whether these supplements could reduce the risk of developing an autoimmune disease, not to treat an existing one. If you already have an autoimmune diagnosis, these findings do not directly address your situation, though there are other lines of evidence supporting the role of vitamin D and omega-3s in disease management as well.
The study also tested just one dose of each supplement — 2,000 IU of vitamin D3 and 1,000 mg of fish oil daily. In my clinical experience, many patients require higher doses of vitamin D to achieve optimal serum levels (typically 50–80 ng/mL of 25-hydroxyvitamin D), especially those with obesity, malabsorption, or limited sun exposure. The study dose should be viewed as a minimum starting point, not a ceiling. Similarly, therapeutic fish oil protocols often involve higher doses of EPA and DHA than were used in VITAL. The fact that meaningful protection was seen even at these modest doses makes the findings more impressive, not less.
For those of you who are in your 50s or older, who have a family history of autoimmune disease, or who are simply committed to supporting long-term immune health, the take-home message from this trial is clear: consistent, long-term use of vitamin D3 and high-quality fish oil — at doses that are safe, affordable, and well-tolerated — may represent one of the most accessible and evidence-backed strategies we have for reducing autoimmune disease risk. This is not speculative. This is 25,000 people, over five years, in a gold-standard trial. That kind of evidence demands our attention.
As always, I recommend working with a knowledgeable healthcare provider to assess your individual vitamin D levels through blood testing, determine the appropriate dose for your body and health history, and select a quality fish oil product that has been third-party tested for purity and potency. Prevention is always preferable to treatment, and in the case of autoimmune disease, this trial gives us rare, powerful evidence that prevention may genuinely be within reach.
Reference
Hahn, J., Cook, N. R., Alexander, E. K., Friedman, S., Walter, J., Bubes, V., Kotler, G., Lee, I. M., Manson, J. E., & Costenbader, K. H. (2022). Vitamin D and marine omega-3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ, 376, e066452. https://doi.org/10.1136/bmj-2021-066452
